Short course of R‐HyperCVAD/MTX/ARA‐C followed by ASCT as first‐line therapy in mantle cell lymphoma patients prolongs progression‐free survival to more than 9 years
Abstract:efforts should aim to improve access to care for all patients with MCL so that they can be evaluated for all available effective therapies.Keywords: autologous stem cell transplantation (ASCT); elderly; mantle cell lymphoma (MCL)
SHORT COURSE OF R-HYPERCVAD/MTX/ ARA-C FOLLOWED BY ASCT AS FIRST-LINE
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.